Abstract

Monoclonal antibodies (mAbs) are now considered as a therapeutic approach to prevent and treat severe viral infections. Using a mouse retroviral model, we showed that mAbs induce protective immunity (vaccinal effects). Here, we investigated the role of natural killer (NK) cells on this effect. NK cells are effector cells that are crucial to control viral propagation upon mAb treatment. However, their immunomodulatory activity during antiviral mAb immunotherapies has been little studied. Our data reveal that the mAb treatment of infected mice preserves the functional activation of NK cells. Importantly, functional NK cells play an essential role in preventing immune dysfunction and inducing antiviral protective immunity upon mAb therapy. Thus, NK cell depletion in mAb-treated, viral-infected mice leads to the upregulation of molecules involved in immunosuppressive pathways (i.e., PD-1, PD-L1 and CD39) on dendritic cells and T cells. NK cell depletion also abrogates the vaccinal effects induced by mAb therapy. Our data also reveal a role for IFNγ-producing NK cells in the enhancement of the B-cell responses through the potentiation of the B-cell helper properties of neutrophils. These findings suggest that preserved NK cell functions and counts might be required for achieving mAb-induced protective immunity. They open new prospects for improving antiviral immunotherapies.

Highlights

  • Neutralizing monoclonal antibodies are considered as promising, high added-value therapeutic agents for the prevention and treatment of severe viral infections, including newly emerging viral infections [1,2,3]

  • We further assessed the functional state of natural killer (NK) cells by measuring the expression of other markers related to NK cell activation (i.e., Ly49D) and antibody-dependent cell-mediated cytotoxicity (ADCC) activity (FcγRs)

  • Our findings suggest that the increased expression of molecules involved in immunosuppressive pathways on dendritic cells (DCs) and CD4+ T cells observed in NK cell-depleted, infected/treated mice might contribute to the abrogation of vaccinal effects observed in these mice together with other cellular and molecular mechanisms involved in immune dysfunction

Read more

Summary

Introduction

Neutralizing monoclonal antibodies (mAbs) are considered as promising, high added-value therapeutic agents for the prevention and treatment of severe viral infections, including newly emerging viral infections [1,2,3]. The high therapeutic potential of antiviral mAbs is due to their multiple mechanisms of action [4,5] Through their Fab (fragment of antigen binding) region, they are able to neutralize virions via the specific recognition of viral determinants required for receptor binding and/or entry into host cells. In addition to playing a key role in viral blunting, the mAb therapeutic effect can be mediated via the induction of protective immunity (vaccinal effect) (reviewed in [6]) which occurs in an Fc-dependent manner [7,8,9,10] Along these lines, we, and others, have shown enhanced humoral and cellular antiviral immune responses upon antiviral antibody therapy in several preclinical models of viral infection [6,10,11,12,13,14,15]. A better understanding of antibody-mediated immunomodulation mechanisms is needed to maximize the therapeutic effect of antiviral mAbs

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call